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States.ARHGAP21 is a 217 kDa RhoGAP protein shown to modulate cell migration through the control of
Cdc42 and FAK activities. In the present work a 250 kDa-ARHGAP21 was identiﬁed by mass spec-
trometry. This modiﬁed form is differentially expressed among cell lines and human primary cells.
Co-immunoprecipitations and in vitro SUMOylation conﬁrmed ARHGAP21 speciﬁc modiﬁcation by
SUMO2/3 and mapped the SUMOylation site to ARHGAP21 lysine K1443. Immunoﬂuorescence stain-
ing revealed that ARHGAP21 co-localizes with SUMO2/3 in the cytoplasm and membrane compart-
ments. Interestingly, our results suggest that ARHGAP21 SUMOylation may be related to cell
proliferation. Therefore, SUMOylation of ARHGAP21 may represent a way of guiding its function.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
ARHGAP21 is a RhoGTPase activating protein (RhoGAP) (ARH-
GAP21) with well-characterized RhoGAP, Pleckstrin Homology
(PH) and PSD-95/Discs-large/ZO-1 (PDZ) domains [1]. ARHGAP21
is a nuclear and perinuclear protein shown to have preferential
GAP activity over Cdc42, to bind to ARF1-GTPase to control vesic-
ular trafﬁcking on Golgi membranes [2], to interact with -catenin,
recruiting this protein to endothelial sites of bacterial invasion [3],
and to control glioblastoma cell migration through its interaction
with FAK and its negative activity over Cdc42 [4]. Although, ARH-
GAP21 is being characterized as an important controller of actin
cytoskeleton dynamics, mechanisms by which ARHGAP21 activity
may be controlled were not yet identiﬁed.
Small ubiquitin-like modiﬁers (SUMOs) are ubiquitin-like poly-
peptides whose conjugation to proteins constitutes a reversible
post-translational modiﬁcation that may control protein function,
subcellular localization and/or expression [5]. In mammals, there
are four SUMO paralogues identiﬁed: SUMO-1 to SUMO-4 [6,7].chemical Societies. Published by E
Hemotherapy Center, Univer-
083-878, Brazil.
lo).
Regenerative Biology, Mount
om 13-02, 10029 NY, UnitedSUMO-2 and SUMO-3 cannot be distinguished from each other in
many contexts, so they are collectively referred as SUMO2/3 [8].
SUMOylation of the majority of substrate proteins occur through
the covalently attachment of SUMO to a lysine (K) in a consensus
sequence KxD/E, although SUMO conjugation may also occur in
non-consensus sites [9]. The SUMOylation machinery consists on
an initial activation of SUMO peptides by sentrin-speciﬁc proteases
(SENP) in mammals [10], to expose a C-terminal diglycine motif
that allow them to be conjugated to an E1 heterodimer SUMO-acti-
vating enzyme (SAE1/SAE2 in vertebrates) with ATP hydrolysis
[11]. The activated SUMO can then be transferred to a cysteine in
the active site of an E2 enzyme, Ubc9, which in turn, can directly
transfer the SUMO peptide or can be brought together with a sub-
strate protein by the action of an E3 ligase enzyme (PIAS, RanBP2,
HDAC, are some examples), resulting in the ultimate SUMO trans-
fer [12]. The SUMO cycle is completed by deSUMOylation mediated
by SENPs. Currently, it’s known that both excessive SUMO conjuga-
tion to proteins or repression of SUMO conjugation can contribute
to tumorigenesis, regardless the tumor type. Thus, the equilibrium
of SUMOylation–deSUMOylation is imperative for cellular mainte-
nance [12].
In the present work, we detected by mass spectrometry a higher
molecular weight form of ARHGAP21, which we demonstrated
to be a SUMOylated form of this protein. We show that ARHGAP21
co-immunoprecipitates and co-localizes exclusively with SUMO2/3lsevier B.V. All rights reserved.
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contrast to the nuclear and perinuclear localization of the
217 kDa form, SUMOylated ARHGAP21 (250 kDa) localizes to the
cytoplasm. All in all we present evidences that the SUMOylation
of ARHGAP21 may be related to the proliferation status of lym-
phoid cells.2. Materials and methods
2.1. Reagents and antibodies
Polyclonal antibody against ARHGAP21 was generated against a
synthetic peptide (KSDSGSLGDAKNEKE), corresponding to residues
1856–1870 of the human protein and afﬁnity puriﬁed by Bethyl
Laboratories, Inc. (Montgomery, Texas). Polyclonal rabbit anti-
ARHGAP21 (sc-98336) and goat anti-beta actin were from Santa
Cruz, mouse monoclonal anti-SUMO1 and anti-SUMO2/3 were
from Abcam (Cambridge, MA). AlexaFluor 488, AlexaFluor 633
and AlexaFluor 555 conjugated secondary antibodies and Pro-
Long Gold antifade reagent with DAPI were from Molecular
Probes (Eugene, OR). Enhanced chemiluminescence reagents were
obtained from GE Health Care (Buckinghamshire, UK). All other
reagent grade chemicals were obtained from Sigma.
2.2. Human cell lines
The human glioblastoma derived cell lines (A172 and T98G), the
cervical carcinoma cell line (HeLa), the acute T cell leukemia cell
line (Jurkat), the acute lymphoblastic leukemia cell line (Molt-4),
the promyelocytic leukemia cell line (HL-60) and the prostate ade-
nocarcinoma cell line (PC-3) were obtained from the American
Type Culture Collection (ATCC). Primary human ﬁbroblasts (FHN)
were kindly provided by Gláucia Santelli Laboratory; ICB, Univer-
sity of São Paulo, São Paulo, Brazil. All cell lines were maintained
as previously described [4].
2.3. Transfection of mammalian cells and protein extraction
1  106 HEK293 cells were seeded on poly-L-lysine (Sigma–
Aldrich, St Louis, MO, USA) coated 100 mm culture dishes and
transiently transfected with 8 lg of plasmid DNA and 12 ll
polyethyleneimine (PEI) (Sigma–Aldrich). After 53 h the cells were
harvested, washed and lysed with 250 ll lysis buffer (RIPA) in the
presence of 20 nM N-ethylmaleimide (NEM) (Sigma–Aldrich).
2.4. Patient samples
Bone marrow (BM) samples from healthy donors (HD), myelo-
dysplastic syndrome (MDS), acute myeloid leukemia (AML) and
acute lymphoblastic leukemia (ALL) patients were collected into
heparin tubes. BM aspirates were collected at the diagnosis, before
any treatment, at the Hematology and Hemotherapy Center of the
University of Campinas. Peripheral blood sample from healthy do-
nors were collected in our donation service. The National Ethical
Committee Board approved the study and all participants provided
informed written consent.
2.5. Mononuclear cell separation and protein extraction
Bone marrow cells from healthy donors (BM-HD), MDS, AML or
ALL patients were isolated by density-gradient through Ficoll-Pa-
que Plus (GE Healthcare, Uppsala, Sweden) according to the man-
ufacturer’s instructions. After cells were separated and washed,
they were lysed in RIPA buffer plus protease inhibitors. Cell ex-
tracts were quantiﬁed using Bradford reagent.2.6. Magnetic separation of CD34+ progenitor cells
BM mononuclear cells were labeled with CD34 MicroBeads.
CD34+ cells were isolated using MACS magnetic cell separation col-
umns (Miltenyi Biotec, Mönchengladbach, Germany) according to
the manufacturer’s instructions. The purity of CD34+ cells was at
least 92% as determined by ﬂuorescence-activated cell sorting
(FACS), using anti-CD34 antibody (Caltag Laboratories, Burlingame,
CA).
2.7. Peripheral blood lymphocytes (PBLs) activation
Buffy coat samples from normal donors of our donation service
were submitted to density-gradient through Ficoll-Paque Plus (GE
Healthcare, Uppsala, Sweden) according to the manufacturer’s
instructions. Mononuclear cells were maintained on plastic dishes
for two hours and, after that, the supernatant containing PBLs was
collected and PBLs were incubated with phytohemagglutinin A
(PHA) for 72 h. After that cells were plated on poly-L-lysine coated
cover slips or cellular extracts were collected in RIPA buffer plus
protease inhibitors.
2.8. Immunoﬂuorescence and laser confocal microscopy scanning
Immunoﬂuorescence was carried out using primary antibodies
against ARHGAP21 (Bethyl Laboratories), SUMO1, and SUMO2/3
(Abcam) (diluted 1:100). Brieﬂy, 2  105 cells were adhered to
poly-L-lysine pre-treated coverslips. Cells were ﬁxed in 4% parafor-
maldehyde-PBS for 20 min and then permeabilized with 0.5% Tri-
ton-X-100 in PBS for 10 min. The cells were incubated with the
indicated primary and secondary antibodies. Finally, coverslips
were mounted on slides using the ProLong Gold antifade reagent
and the cells were analyzed by Confocal laser scanning on a LSM
510 (Zeiss, Welwyn Garden City, UK) mounted over an Axioplan
microscope (Zeiss) using 40X or 63X 1.3 NA oil immersion objec-
tives. Protein colocalization was quantiﬁed by Pearson’s coefﬁcient
using the Colocalization Finder plugin from ImageJ free image
analysis 180 software (W. Rasban, National Institutes of Health).
2.9. Immunoprecipitation and Immunoblotting
Cell extracts were collected in SDS-sample buffer and diluted in
PBS-0.5% NP-40 plus protease inhibitors before immunoprecipita-
tion (for SUMO immunoprecipitation), or lysed in RIPA buffer plus
protease inhibitors for anti-ARHGAP21 immunoprecipitation.
Brieﬂy, 500 lg of total cell extracts were incubated overnight with
5 lg of the speciﬁed antibodies or IgG isotype used as a negative
control. The immune complexes were precipitated with protein-
A-Sepharose 50% slurry (GE), washed with PBS-0.5% NP-40 to
remove unspeciﬁc proteins that might be bound to the complex,
and then analyzed by 8% or 5–15% SDS–PAGE and immunoblotted
with the antibodies of interest.
2.10. Mass spectrometry analysis
Protein content from T98G cells were extracted in 7 M urea, 2 M
thiourea, 4% CHAPS, 100 mMDTT and fractionated in 8% SDS–PAGE.
The gel was stained with 0.5% Coomassie-Brilliant Blue, destained
and gel bands of 250 and 200 kDa were excised and submitted to
in-gel digestion [13] using sequencing-grade modiﬁed porcine
trypsin (Promega). Peptides were puriﬁed using C18 ZipTips
(Millipore) and eluted directly with a matrix solution of 2% w/v
a-cyano-4-hydroxycinnamic acid (Sigma), 60% acetonitrile, and
0.1% v/v TFA in the sample plate. Peptides were analyzed on a
Voyager DE-PRO matrix-assisted laser desorption/ionization time-
of-ﬂight (MALDI-TOF) mass spectrometer (Applied Biosystems,
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using trypsin autodigestion products (842.509, 1045.563, and
2211.104 Da). The masses of monoisotopic peaks were searched
against the National Center for Biotechnology Information (NCBI)
database using the web-based software MS-Fit from University of
California, San Francisco (http://prospector.ucsf.edu/prospector/
cgi-bin/msform.cgi?form=msﬁt standard).
2.11. Plasmids and ARHGAP21 mutagenesis
The full human ARHGAP21 (NM_020824.3) coding sequence
(nucleotides 488-6361) was ampliﬁed by PCR from a pEGFP-ARH-
GAP21 plasmid kindly provided by Dr. Philippe Chavrier (Institute
Curie, Paris, France) using the Phusion high ﬁdelity Taq polymer-
ase (Finnzymes, Thermo Fisher Scientiﬁc Inc., Finland) and primers
with adapters to directly clone it into EcoRI and NotI sites on
pGEX-5X1 plasmid (F: 50 GAATTCAATGAAATGATGGCCACGCGTCGG
30 and R: 50 CCGACGCGTGGCCATCATTTCATTGAATTC 30). ARH-
GAP21 SUMOylation sites predicted by at least two softwares
(K1089, K1101, K1443 and K1722, according to SUMOplot, SU-
MOsp and PHOSIDA SUMOylation) were mutated using Quick-
change site-directed mutagenesis kit (Stratagene, Ambion, Inc.)
following the manufacture’s instructions. ARHGAP21 integrity
and the success of mutations were veriﬁed by sequencing.
2.12. Expression of recombinant GST-ARHGAP21-WT
GST-ARHGAP21-WT or SUMOylation mutants (K1089T, K1101Q,
K1443Q and K1722Q) cloned into pGEX-5X1 vector were ex-
pressed in Escherichia coli BL21-Codon Plus strain (GE Healthcare)
or Rosetta™(DE3)pLysS (Novagen, Merck, Darmstadt, Germany)
following manufacture’s instructions. Brieﬂy, bacterial cells
transformed with pGEX-ARHGAP21-WT, pGEX-ARHGAP21K1101Q,
pGEX-ARHGAP21K1089T, pGEX-ARHGAP21K1443Q or pGEX-ARH-
GAP21K1722Q grown overnight were inoculate on 2YT medium
containing 100 lg/ml ampicillin until OD600 = 0.8-1. Recombinant
protein expression was induced by 1 mM IPTG for 2 h at 30 C.
After this period, bacterial cells were harvested and lysed by
sonication on PBS buffer containing 1% Triton-X-100, 2 mM PMSF
and complete protease inhibitors-cocktail (EDTA-free, Roche).
The amount of recombinant protein expressed was analyzed by
8%-SDS–PAGE and Coomassie-Brilliant Blue staining.
2.13. In vitro SUMOylation assay
SUMOylation of ARHGAP21 protein was veriﬁed in vitro using
the ENZO SUMOylation Kit following the manufacture’s instruc-
tions. Brieﬂy, recombinant ARHGAP21-WT, ARHGAP21K-1101-Q,
ARHGAP21K-1089-T, ARHGAP21K-1443-Q and ARHGAP21K-1722-Q were
incubated with the recombinant SUMO1, SUMO2 or SUMO3 in
the presence of SUMO-E1, SUMO-E2 and Mg-ATP to verify which
SUMO isoform modiﬁes ARHGAP21. As controls, respectively, Ran-
GAP1 protein was used as substrate for SUMO1 reaction (positive)
and the RanGAP1 was used in a SUMO1 reaction without Mg-ATP
(negative).
3. Results
3.1. ARHGAP21 has two forms
ARHGAP21 predicted molecular weight is 217 kDa. The rabbit
polyclonal antibody we used was raised against a speciﬁc immuno-
genic C-terminal localized peptide and according to the tissue or
cellular type it recognizes a slower migrating band. The majority
of cell lines samples shown in Fig. 1A display both ARHGAP21
forms (black and grey arrows), but the amount of each formexpressed among the cell lines are slightly different. This is the case
of the two closely related glioblastoma cell lines, A172 and T98G,
that display different amounts of the 217 kDa band (black arrow).
Whilst the majority of the cell lines express both ARHGAP21 forms,
interestingly, the two lymphoblastic-derived cell lines (Molt-4 and
Jurkat) barely express the 217 kDa form. In order to test if this
slower migrating form was a modiﬁed ARHGAP21 form, we immu-
noprecipitated endogenous ARHGAP21 in T98G cell extracts and
immunoblotted with anti-ARHGAP21 antibody (Fig. 1B). As evi-
denced, anti-ARHGAP21 antibody precipitated both 217 and
250 kDa forms. Intriguingly, HEK293 cells transfected with a plas-
mid containing the entire ARHGAP21 coding sequence display also
the two pattern band when their extracts were submitted to Wes-
tern blotting (Fig. 1C), indicating that this 250 kDa band represents
a post-translational modiﬁed form of ARHGAP21.
In order to ﬁnally identify if this 250 kDa form is truly ARH-
GAP21, we submitted T98G 217 and 250 kDa molecular weight
bands to in-gel digestion and analysis by MALDI-TOF. The spec-
trums of masses generated by both gel bands are shown on
Fig. 1D and E, respectively, and the marked masses correspond to
masses of peptides belonging to ARHGAP21. These results conﬁrm
that the 250 kDa band corresponds to a modiﬁed form of the ARH-
GAP21 protein.
3.2. ARHGAP21 is SUMOylated
Searching for possible post-translational modiﬁcations that
could confer molecular weight increase to ARHGAP21 we found
SUMOylation as the possible one. Submission of ARHGAP21 se-
quence to SUMOsiteprediction (SUMOsp2.0) software [14] resulted
on the indication of 6 potentially SUMOylated lysines, whose posi-
tions on ARHGAP21 protein are schematically represented (Fig. 2A).
We performed co-immunoprecipitation experiments on T98G
cell extracts in order to check if ARHGAP21 is SUMOylated. Inter-
estingly, we found ARHGAP21 to co-immunoprecipitate exclu-
sively with anti-SUMO2/3 antibody (Fig. 2B). Since SUMO cycle
involves de-SUMOylation by SENPs, which are cysteine proteases,
we overexpressed ARHGAP21 in HEK293 cells and collected the
extracts in the presence of N-ethylmaleimide (NEM), a general cys-
teine protease inhibitor known to inhibit protein de-SUMOylation
by SENPs. Interestingly, NEM presence favors the appearance of
the 250 kDa ARHGAP21 (Fig. 2C). These results indicate that
ARHGAP21 is modiﬁed by SUMO2/3.
In order to corroborate this data, we used the recombinant
GST-ARHGAP21-WT (Fig. 2D) as well as the SUMOylation mutants
(ARHGAP21K-1101-Q, ARHGAP21K-1089T, ARHGAP21K-1443-Q and
ARHGAP21K-1722-Q) as substrates for in vitro SUMOylation reac-
tions. It was veriﬁed that ARHGAP21-WT is equally SUMOylated
by both SUMO2 and SUMO3 peptides (Fig. 2E), but not by SUMO1.
The RanGAP protein, which is known to be SUMOylated equally by
SUMO1, SUMO2 and SUMO3, was used as control in reaction with
SUMO1 peptide, showing its SUMOylation by SUMO1, which was
abrogated in the absence of Mg-ATP (negative control). ARHGAP21
SUMOylation mutants were submitted to in vitro SUMOylation as-
say using SUMO3 peptides, sinceWT-ARHGAP21 is equally SUMOy-
lated by both SUMO2 and SUMO3. After the reaction, samples were
submitted to Western blotting with both anti-ARHGAP21 and anti-
SUMO2/3 antibodies. All recombinant proteins were SUMOylated,
except for ARHGAP21K-1443-Q mutant (Fig. 2F), which blocked
SUMOylation by SUMO3. Thus we identiﬁed the lysine (K) at posi-
tion 1443 as a target site for ARHGAP21 SUMOylation.
3.3. SUMOylated ARHGAP21 is cell type dependent
Since we observed a striking prevalence of ARHGAP21 SUMOy-
lated form on hematopoietic cells, namely T-cells (Molt-4 and
Fig. 1. Identiﬁcation of a higher molecular weight ARHGAP21 form. (A) Western blotting of several human cell lines with anti-ARHGAP21 antibody displaying two bands, the
predicted 217 kDa and one slower migrating band of approximately 250 kDa. (B) Immunoprecipitation of ARHGAP21 from T98G extracts (lanes 2 and 3) corroborates the
identiﬁcation of the 250 kDa band as an ARHGAP21 form, found on the input (ﬁrst lane). (C) ARHGAP21 overexpression on HEK293 cells results in the appearance of the high
molecular weight form of ARHGAP21. (D and E) MALDI-TOF MS spectrums generated, respectively, from 217 to 250 kDa samples digested with trypsin-Gold (Promega).
Highlighted masses correspond to masses of peptides from the ARHGAP21 protein, which were found in both molecular weight bands.
Fig. 2. ARHGAP21 is SUMOylated by SUMO2/3. (A) Schematic representation of ARHGAP21 protein showing lysines (K) in SUMO-binding conserved motifs. (B)
Immunoprecipitation of T98G cell extracts with anti-SUMO1 or anti-SUMO2/3 antibodies and probing with anti-ARHGAP21 antibody, evidencing speciﬁcally ARHGAP21 co-
immunoprecipitation with anti-SUMO2/3. I = input. (C) Presence of a cysteine protease inhibitor (N-ethylmaleimide–NEM) in HEK293 cells overexpressing ARHGAP21
increases the amount of SUMOylated ARHGAP21 (grey arrow). (D) IPTG-induced expression of recombinant GST-ARHGAP21-WT. T = total bacterial extract, P = puriﬁed
bacterial extract. (E) In vitro SUMOylation assay using recombinant GST-ARHGAP21-WT as a substrate evidenced equally SUMOylation by both SUMO2 and SUMO3.
Recombinant RanGAP1 protein was used as control for in vitro SUMOylation by SUMO1. (F) In vitro SUMOylation assay using recombinant ARHGAP21-mutants as substrates.
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form in primary bone marrow cells derived from patients with
myelodysplastic syndrome (MDS), acute myeloid leukemia
(AML), acute lymphoblastic leukemia (ALL) as well as normal
peripheral blood mononuclear cells from healthy donors (PBMC-
HD). Western blot analysis showed that SUMOylated ARHGAP21
was encountered exclusively in PBMC-HD and ALL samples
(Fig. 3A).
Since there are different maturation status of cell types among
both peripheral blood and bone marrow cells, we fractionated pro-
genitor CD34+ cells from healthy donor peripheral blood samples
and found ARHGAP21 only at its predicted molecular weight
(217 kDa) (Fig. 3B). We also analyzed ARHGAP21 subcellular distri-
bution in hematopoietic cells. In both PBMC-HD and MDS samples,
ARHGAP21 was found in the cytoplasm. The zoomed areas from
‘‘merge’’ panels clearly display ARHGAP21 co-localization with
SUMO2/3 only in PBMC-HD (yellow regions, Fig. 3C).
3.4. ARHGAP21 SUMOylation may be involved in cell proliferation
We next examined ARHGAP21 expression levels after resting
human peripheral blood lymphocytes (PBLs) were induced to
proliferate with phytohemagglutinin A (PHA). Interestingly, non-Fig. 3. Differential SUMOylation of ARHGAP21 forms in hematopoietic cells. (A) ARHGAP
from myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and acute lymp
cells from healthy donors (PBMC-HD). (B) Comparison of ARHGAP21 forms expression o
MDS patient or from a healthy donor (PBMC-HD) were co-immunostained with anti-ARH
market on Merge panels, and were magniﬁed to show co-localization of ARHGAP21 and S
MDS cells, corroborating Western blotting results shown in A.activated lymphocytes display the majority of ARHGAP21 in its
predicted 217 kDa form, but there are some SUMOylation, while
PHA treated lymphocytes display ARHGAP21 mostly SUMOylated
(Fig. 4A, black and red arrows, respectively). The differential ARH-
GAP21 SUMOylation pattern in lymphocytes extracts was also evi-
denced by a slightly stronger band of co-immunoprecipitated
ARHGAP21 on the lane with PHA-treated lymphocytes precipitated
with SUMO2/3 antibody (Fig. 4B, left upper panel). In addition, we
show in the reverse experiment that SUMO2/3 co-precipitates with
precipitated ARHGAP21 protein in both non-treated and PHA-trea-
ted lymphocytes (Fig. 4B, right upper panel). Moreover, ARHGAP21
and SUMO2/3 co-localized in PHA-treated lymphocytes (Fig. 4C), as
evidenced by the Pearson’s colocalization coefﬁcient values, cor-
roborating the preferential ARHGAP21 SUMOylation on lympho-
cytes activated to proliferate. Supporting these observations,
ARHGAP21 and SUMO1 do not co-localize in proliferating lympho-
cytes (Fig. 4C, bottom panels).
4. Discussion
In the present work we identify by mass spectrometry a novel
250 kDa form of the ARHGAP21 protein. This form was found in
several cell lines analyzed and there is a rather different level of21 expression was analyzed by Western blotting of bone marrow mononuclear cells
hoblastic leukemia (ALL) patients, in comparison to peripheral blood mononuclear
n normal CD34+ cells versus PBMC-HD. (C) Bone marrow mononuclear cells from a
GAP21 and anti-SUMO2/3 antibodies. The right panels correspond to zoomed areas
UMO2/3 in BM-HD (yellow regions), whereas there are few or no co-localization on
Fig. 4. ARHGAP21 is preferentially SUMOylated on proliferating lymphocytes. (A) Western blotting of ARHGAP21 expression on PHA treated lymphocytes showing
preferential SUMOylation of ARHGAP21 on highly proliferating PHA treated cells. (B) lymphocyte extracts (0 and 72 h-PHA treated) were submitted to immunoprecipitation
with SUMO2/3 (left panel) and ARHGAP21 (right panel) antibodies and isotype controls. Immunoblotting was performed with anti-ARHGAP21 and anti-SUMO2/3. (C)
Lymphocytes (0 h or 72 h-PHA treated) were adhered to coverslips and co-immunostaining evidenced ARHGAP21 and SUMO2/3 higher co-localization on PHA-activated
lymphocytes (Pearson’s colocalization coefﬁcient = 0.12), in opposition to non-colocalization between ARHGAP21 and SUMO1 (Pearson’s colocalization coefﬁcient = 0.006).
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molecular weight increase from the 217 kDa predicted for ARH-
GAP21 to approximately 250 kDa would imply post-translational
modiﬁcations.
In silico analysis indicated that ARHGAP21 could be possibly
SUMOylated. The SUMOsp 2.0 software displayed six possible
SUMOylated lysines on ARHGAP21, ﬁve of which relies on consen-
sus KxD/E site (K158, K1089, K1101, K1443 and K1722) and one on
a non-consensus site (K1459). Currently, its known that 75% of
SUMOylation occurs on lysines within the consensus sequences
[9]. To corroborate in silico ﬁndings, co-immunoprecipitation and
in vitro SUMOylation experiments showed speciﬁc ARHGAP21
SUMOylation by SUMO2 and SUMO3. Moreover, replacement of
single predicted lysines (K1089, K1101, K1443 and K1722) in the
recombinant protein abrogated ARHGAP21 SUMOylation only on
K1443. Thus we identiﬁed ARHGAP21 K1443 as the target site
for SUMOylation by SUMO3.
SUMO2/3 peptides are known to exist in higher concentrations
within cells than SUMO1 [15] and also, SUMO2/3 can form conju-
gated chains through a single lysine [7,16]. Since each SUMO-2/3
peptide may have 11 or 13 kDa, respectively, it is conceivable that
ARHGAP21 receive a chain in its lysine 1443. Nevertheless one can-not exclude the possibility that ARHGAP21 might be SUMOylated
concomitantly in additional residues.
The exclusively SUMOylation of ARHGAP21 in PBMC-HD and
on ALL samples is really intriguing. But when we separated
lymphocytes from mononuclear cells ARHGAP21 appeared
preferentially non-SUMOylated on resting lymphocytes and
preferentially SUMOylated on proliferating lymphocytes, which
indicates that the post-translational modiﬁcation of ARHGAP21
by SUMO2/3 may be involved in proliferation events in these cell
types. Recently, ARHGAP21 was described to be phosphorylated
on certain cell cycle phases [17], further indicating that post-
translational modiﬁcation might be an important and recurrent
mechanism for controlling ARHGAP21 activity in proliferating
cells.
Since SUMOylation-deSUMOylation cycles can be highly dy-
namic and as protein SUMOylation is being attributed as an impor-
tant event in controlling many aspects of cell physiology, including
cell cycle regulation, transcription, nucleo-cytoplasmic transport,
DNA replication and repair, chromosome dynamics, apoptosis
and ribosome biogenesis [18], the identiﬁcation of ARHGAP21 as
a SUMO substract indicates that the ﬁne-tuning of ARHGAP21
function is controlled by SUMOylation events.
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